 Evelo Biosciences, Inc. EVLO, a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today provided an update on recent positive regulatory interactions on the EDP1815 Phase 2 trial design, resulting in a reduction in the overall development plan timeline to registration. In 2019, we reported positive clinical data with EDP1815 in individuals with psoriasis, which was the first clinical evidence of the promise that Sintax holds as a new drug target. 